Prüftechnik ShaftAlign Touch Laser Alignment System Enables Technicians to Quickly and Precisely Align the Majority of Standard Machines
16.9.2020 13:00:00 EEST | Business Wire | Press release
Prüftechnik, a division of Fluke Reliability, introduces the ShaftAlign Touch laser alignment system, a new digital solution that exceeds the capabilities of conventional tools and delivers greater speed and accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005134/en/
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. (Photo: Business Wire)
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. Prüftechnik Adaptive Alignment systems, such as the ShaftAlign Touch, automatically eliminate user errors and low-quality measurement points by adapting to the asset, the alignment situation, and the technician who is performing the job. Cloud-compatible software allows newer technicians to share measurements with more experienced colleagues or consultants — inside the plant or across the globe — to complete a job.
“ShaftAlign Touch is a significant improvement over conventional shaft alignment measurement equipment and basic laser systems in the market,” said Ankush Malhotra, vice president and general manager of Fluke Reliability. “With its intuitive computer-based, guided user interface, single-laser technology, and cloud-transfer capabilities, ShaftAlign Touch, sets a new benchmark for solving alignment issues at an unbeatable price/performance ratio.”
ShaftAlign Touch delivers:
- High performance and precise results — ShaftAlign Touch leverages single-laser technology to provide high-precision, high-performance alignment measurements.
- Quick setup and intuitive user interface — its swift setup and tablet-like, intuitive guided user interface make it more user-friendly than any of the conventional alignment measurement methods.
- Ability to share data via the cloud — technicians can leverage its integrated Wi-Fi cloud solution to easily transfer measurement data from the ShaftAlign Touch handheld device to the ARC 4.0 software.
ShaftAlign Touch is the latest addition to the family of Prüftechnik Adaptive Alignment laser systems. Adaptive Alignment is a combination of software and hardware that enables maintenance and reliability teams to adjust to most any horizontal, angular, or vertical alignment challenge. With Adaptive Alignment solutions, work is completed faster, results are more accurate, and team capabilities are better utilized compared to other market solutions.
For more information on the Prüftechnik ShaftAlign Touch, visit https://www.pruftechnik.com/en-US/Products-and-Services/Alignment-Systems-for-Rotating-Machinery/Shaft-Alignment/Shaft-Alignment-Systems/SHAFTALIGN-touch/.
About Prüftechnik
Prüftechnik is a worldwide provider of maintenance technology with a comprehensive product, service, and training program tailored to the needs of maintenance experts in shaft alignment, vibration analysis, condition monitoring, and destruction-free testing. Many manufacturing companies worldwide trust its solutions for reliable and condition-based maintenance of rotating machines. For more information, visit https://www.pruftechnik.com.
About Fluke Reliability
Fluke Reliability offers reliability and maintenance teams the tools, software, and services they need to optimize asset performance. Home to three powerful iconic brands – Prüftechnik, eMaint, and Fluke Connect – Fluke Reliability serves more than 70,000 customers worldwide with a relentless dedication to quality, innovation, and service. Its products inform customers on the health of their assets, and its software and services drive better maintenance decisions – improving productivity, driving uptime, and reducing costs. For more information, visit https://www.accelix.com.
FLUKE is a registered trademark of Fluke Corporation. For more information, visit the Fluke website.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005134/en/
Contact information
Barbara Ellis
(425) 446-4949
barbara.ellis@fluke.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom